T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety ...

Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, ...

Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) ...

The CAR product co-expresses a protein, called somatostatin receptor 2, which allows clinicians to monitor the therapy’s effectiveness with a specialized positron emission tomography (PET ...

Molecular imaging, including somatostatin receptor scintigraphy but more so PET with specific tracers, such as C 11-5HTP or Ga 68-DOTA octreotate, will improve staging and follow-up of therapy in ...

which targets a somatostatin receptor and is also in a late-stage trial. Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and ...

The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR ...